BGV (BioGeneration Ventures)

We are pleased to announce that BGV (BioGeneration Ventures) portfolio company Tessellate BIO, a preclinical-stage biotech company advancing innovative Synthetic Lethality approaches in precision oncology, has appointed Dr. Lara Boyd as Chief Business Officer. Dr. Boyd brings a wealth of expertise in biotech business strategy and partnerships, making her a key addition to Tessellate’s mission to develop breakthrough cancer therapies. Her leadership will be instrumental as Tessellate Bio continues to push the boundaries in targeted oncology. Congratulations to Dr. Lara Boyd and the entire Tessellate team on this exciting new chapter! #oncology #moversandshakers #lifesciences #biotech Daniela Couto Keno Gutierrez

BGV (BioGeneration Ventures) announces portfolio company Kivu Bioscience's successful $92M Series A financing round. Kivu Bioscience is pushing boundaries in the field of antibody-drug conjugates (ADCs), leveraging the innovative Synaffix BV platform to enhance efficacy and reduce off-target toxicity. This significant funding will support the clinical development of multiple ADC programs, accelerating the company's path toward groundbreaking cancer therapies. Backed by Novo Holdings and joined by Gimv, Red Tree Venture Capital, HealthCap, and long-standing supporters M Ventures , BOM, and BGV, Kivu is positioned to make a substantial impact in ADC drug development under the expert leadership of Mohit Trikha, PhD. With decades of experience, Dr. Trikha and his world-class team are driving towards pivotal milestones that will reshape the treatment landscape. Click on the following link to learn more: https://lnkd.in/gexBkmbD #BioGenerationVentures #KivuBioscience #SeriesA #ADCs #Biotech #VentureCapital #LifeSciences #CancerResearch

We are proud to share that Tessellate BIO, one of our portfolio companies, has been featured in Drug Discovery World. The article titled “The Promise of Synthetic Lethality in Precision Oncology”, authored by Tessellate’s Head of Discovery Biology, Katie Chapman, and CSO, Jürgen Moll, PhD, explores novel approaches to target cancer cells that rely on alternative lengthening of telomeres (#ALT). For an in-depth look, head to pages 32-34 to read about these groundbreaking insights in synthetic lethality for precision oncology using the following link: https://lnkd.in/e-xvXETT #DrugDiscovery #Cancer #PrecisionOncology #Innovation #lifesciences #biotech Daniela Couto Keno Gutierrez Diede Brunen Andree Blaukat Andrew Lightfoot PhD MBA

We are thrilled to share the BGV (BioGeneration Ventures) Impact Report 2023, which highlights our portfolio companies' contributions to scientific innovation and the clinical development of new therapies over the past year, has been published. This year, we have expanded our reporting efforts in response to the increased demand for environmental, social, and governance (ESG) data, especially following the EU Sustainable Finance Disclosure Regulation (SFDR). By leveraging the life sciences VC ESG Reporting template, we have gathered more in-depth ESG-related insights from our portfolio companies, demonstrating our commitment to sustainability and transparency. At BGV, we are dedicated to integrating impact and ESG considerations into our overall strategy, ensuring we meet industry standards, regulatory requirements, and the growing expectations of our investors. We also remain steadfast in supporting our portfolio companies as they work to make a meaningful impact on patients' lives across various disease areas. Read the full report to learn more about our journey and the progress made in 2023: https://lnkd.in/eT_WCdWS #ImpactReport2023 #ESG #LifeSciences #Innovation #Sustainability #Biotech #VentureCapital Silva Deželan, PhD Elisa Camorani Oskar Slotboom Edward Van Wezel

We are pleased to share an important development from our portfolio company, Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs). Confo Therapeutics has announced the publication of groundbreaking research in Nature Communications, presenting the world’s first structure of a complex between an antibody-based agonist and a Class A GPCR. This achievement specifically focuses on the melanocortin receptor 4 (MC4R), a critical component of the melanocortin receptor family and a key regulator in the leptin-melanocortin molecular axis, which governs hunger and satiety. This significant advancement underscores Confo’s ongoing commitment to pioneering new therapeutic pathways in the treatment of diseases involving GPCRs. Click on the following link to learn more: https://lnkd.in/ehckZdp4 #BGV #ConfoTherapeutics #GPCRResearch #LifeSciencesInnovation #ObesityResearch #lifesciences #biotech Edward Van Wezel Diede Brunen

We are excited to announce that Tanai Therapeutics, a VIB spin-off, has secured additional funding from Novo Nordisk and BGV (BioGeneration Ventures) alongside existing investors V-Bio Ventures, Qbic Fund | Venture Capital and VIB, to accelerate the development of its first-in-class, oral therapeutic for obesity. This brings the total seed round to over EUR 6 million. With the appointment of a world-renowned Scientific Advisory Board, including Prof. Savvas Savvides, Prof. Bill Haynes, Prof. Susanne la Fleur, Prof. Sir Stephen O’Rahilly, Prof. Mads Tang-Christensen, and Prof. Matthias H. Tschöp, Tanai is poised to make significant advancements in tackling obesity through its innovative approach. This strong investor syndicate and expert board underscore the high potential of Tanai’s novel treatment. We are proud to support Tanai on its mission to address one of the most pressing health challenges of our time. Click the following link to read more: https://lnkd.in/gC9zM2TA Rianne Ellenbroek #BGV #PortfolioNews #ObesityTreatment #Biotech #Innovation #NovoNordisk #Healthcare #VIB #TanaiTherapeutics #lifesciences #biotech

The European Innovation Summit (EIS) - A European Society of Retina Specialists (EURETINA) event - is happening today, September 18, 2024 in Barcelona. This event fosters collaboration between industry leaders, regulators, investors, researchers, and physicians, all focused on innovations in the retinal space. BGV (BioGeneration Ventures) Managing Partner Edward Van Wezel will participate in Session 4: The Investor Panel which takes place at 15:05 CET. This marks the second major conference in Barcelona today for the BGV team. Click on the following link for more information: https://lnkd.in/ginHte5u #EIS2024 #lifesciences #Biotech #RetinalInnovation #Investors #Collaboration #BGV Edward Van Wezel

Retina Forum 2024, part of the Ophthalmology Futures Forums, will take place at Esferic, Barcelona, on Wednesday, 18 September 2024. This clinician-driven event will spotlight innovation in ophthalmic healthcare, focusing on groundbreaking technologies, entrepreneurial ventures, market access, and the commercialization of ophthalmic devices, diagnostics, and pharmaceuticals. General Partner Daniela Couto will chair Panel 6: The Retina Business: Do the Few Wins Justify the Many Losses? at 15:30. Do not miss out on this insightful discussion with experts shaping the future of retinal healthcare. Click on the following link to learn more: https://lnkd.in/gv78K6F6 #Ophthalmology #RetinaForum2024 #HealthcareInnovation #MedicalDevices #Entrepreneurship #OphthalmicInnovation Daniela Couto -

BGV (BioGeneration Ventures) portfolio company AZAFAROS B.V. has announced that data from the ongoing double-blind, placebo-controlled Phase 2 RAINBOW study investigating its lead asset, nizubaglustat in patients with Niemann-Pick disease type C (NPC) or GM2 gangliosidosis, were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM 2024 Annual Symposium) in Porto, Portugal. The results of part one of the study, designed to determine the safety, #pharmacodynamics, and #pharmacokinetics of Azafaros' lead asset nizubaglustat, demonstrated the compound had a positive safety profile and was well-tolerated in the 13 participants in the study. All patients are now enrolled in the extension phase of the trial, where initial unblinded data on 10 patients showed 8 had improved or stabilized SARA (Scale for the Assessment and Rating of Ataxia) scores. Additionally, a reduction in seizure frequency was observed for the participants who had experienced daily seizures before recruitment into the study. Data from the RAINBOW study will be used to inform the target dose for Azafaros’ planned Phase 3 pivotal studies, due to be initiated 2025. Click on the following link to read more: https://lnkd.in/en84m-QW #lifesciences #biotech #NiemannPick Edward Van Wezel

Considering a career in venture capital? BGV is opening up two new positions for a Fellowship and an Analyst. We are a European venture capital firm specialised in early stage investments in biotech companies developing truly disruptive solutions for diseases with high unmet medical needs. The roles offer personal and professional growth in a dynamic environment, exposing you to company evaluations, due diligence, and collaboration with industry experts. You will learn and work alongside a diverse and international team of investors with extensive experience in the life sciences. Click on the following link to get more details of both positions: https://lnkd.in/e25S4ATV   #LifeSciences #VentureCapital #Biotech #Investment #career #opportunity #hiring